Zepbound®
FDA-approved tirzepatide for chronic weight management
Zepbound® is the FDA-approved brand of tirzepatide indicated for chronic weight management in adults and for moderate-to-severe obstructive sleep apnea in adults with obesity. Made by Eli Lilly, it is a once-weekly subcutaneous injection available as single-dose vials and the KwikPen pre-filled pen. Zepbound® activates both GLP-1 and GIP receptors and has produced the largest average weight loss of any FDA-approved weight-management therapy to date in head-to-head data.
Common reasons patients ask about Zepbound:
Data
Zepbound® is supported by the SURMOUNT phase 3 program. In SURMOUNT-1, the 15 mg dose produced an average body weight reduction of about 22.5% at 72 weeks compared to placebo. SURMOUNT-OSA later studied tirzepatide in adults with moderate-to-severe obstructive sleep apnea and obesity, producing meaningful reductions in apnea-hypopnea index alongside weight loss — leading to the first FDA-approved drug for OSA in this population.
~22.5%
Average body weight reduction at 72 weeks on Zepbound® 15 mg in SURMOUNT-1
2023
FDA approval for chronic weight management
SURMOUNT-OSA
First FDA-approved medication for moderate-to-severe OSA in adults with obesity
How it works
Zepbound® delivers tirzepatide, which activates both GLP-1 and GIP receptors. GLP-1 reduces appetite and slows gastric emptying; GIP adds a complementary metabolic signal that improves how the body uses glucose and lipids. Together they create a more complete appetite and metabolic effect than GLP-1 alone.
Activates GLP-1 receptors
Reduces appetite and slows gastric emptying.
Activates GIP receptors
Adds a complementary metabolic signal to improve glucose and lipid handling.
Eligibility
Generally a good fit for
Not appropriate for
A starting point your provider considers alongside your full health profile.
BMI is a screening tool, not a diagnosis. Your provider will review your full health profile during the intake to determine eligibility.
Your BMI
—
Journey
Weeks 1–4
Weeks 5–12
Months 3+
Ongoing
Side effects
Zepbound® shares the GLP-1-class side-effect profile, with GI symptoms most common. Pacing titration is the single biggest lever for tolerability.
Common
Less common but serious
If you have questions about whether Zepbound is right for you, your PreventiveMD provider will review your full health history once you get started.
Dosing
Zepbound® vials are titrated from 2.5 mg weekly to a maintenance dose of 5, 7.5, 10, 12.5, or 15 mg weekly, with increases every four weeks as tolerated. Specific dose is set by your provider based on goals and tolerance.
How to inject
The Zepbound® KwikPen is a multi-dose pre-filled pen titrated on the same weekly schedule as the vials: starting at 2.5 mg once weekly, increasing in 2.5 mg steps every four weeks as tolerated. Maintenance doses are 5, 7.5, 10, 12.5, or 15 mg weekly; for OSA, the FDA-approved maintenance is 10 mg or 15 mg weekly. Specific dose is set by your provider based on goals and tolerance.
How to inject
Seek emergency care immediately if you experience difficulty breathing or swallowing, swelling of the face, lips, tongue, or throat, hives or a widespread rash, dizziness or fainting, or a rapid heartbeat. These can be signs of a serious allergic reaction.
Pricing
Loading pricing…
FAQs
Both contain tirzepatide. Zepbound® is an FDA-approved finished drug product manufactured by Eli Lilly with standardized dosing and delivery. Compounded tirzepatide is prepared by a pharmacy under physician supervision for individual patients — a different regulatory pathway.
Continuing at or near your current dose is a very common case that we accommodate, however the final call is always going to be based on your PreventiveMD provider’s review of your overall medical history.
How we accommodate this: when you get started from our website, you will fill out a form that asks about your GLP-1 history and what dosing you'd prefer, if any. You may also upload your previous prescription so your provider can review your request with ease.
It depends. We don't recommend extremely low calorie diets because they can worsen side effects. Choose a variety of nutrient-dense foods each day, including colorful fruits and vegetables, whole grains, healthy fats, dairy and lean proteins. Eating adequate protein (20-30 grams per meal) and fiber each day can help minimize unwanted disgestive side effects while promoting weight loss and maintaing lean muscle mass.
Vials may be more cost-effective in some pricing programs; the KwikPen offers a more streamlined injection experience without drawing from a vial. Your provider can help you choose based on cost, convenience, and comfort.
No. Currently, labs aren't required to get started. Your provider will review your medical questionnaire responses to confirm if the medication is appropriate for you.
Yes, completely. Vials are filled to your exact prescribed volume, not to the top of the glass. Check the total mL printed on the sticker label. If anything still looks off, send us a photo of the label and we’ll verify it against your prescription.
Most patients notice reduced appetite within the first two weeks and visible weight loss within 1–2 months. Average results in SURMOUNT-1 continued building through 72 weeks.
Reach out to your PreventiveMD Care Team so they can connect you to your provider for guidance. Your provider can prescribe anti-nausea medication (e.g., Zofran/ondansetron) to a local pharmacy of your choice, where you'll have to pay for it separately.
How to get started
Option A
For returning patients, or anyone who already knows the protocol they’re after.
Option B
New to this? Take a 5-minute assessment and get matched to options for your goals.